These findings are consistent with observation of synergistic anti-tumour effect of treatment with ARB and AT2R agonist medication combined in comparison to either alone and suggest a therapeutic benefit in the dual regulation of AT1R and AT2R in ovarian cancer [24]. This evidence concerns the gene AGTR1 and ovarian cancer.